NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) are two of the hottest…
Buy
80
TMDX Quote, Financials, Valuation and Earnings
Last price:
$123.36
Seasonality move
:
18.31%
Day range:
$118.79 - $124.14
52-week range:
$55.00 - $177.37
Dividend yield:
0%
P/E ratio:
90.69x
P/S ratio:
9.23x
P/B ratio:
15.67x
Volume:
750.2K
Avg. volume:
1.2M
1-year change:
-9.95%
Market cap:
$4.2B
Revenue:
$441.5M
EPS (TTM):
$1.36
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TMDX
TransMedics Group
|
$123.4M | $0.24 | 28.29% | 22.47% | $126.71 |
|
AXGN
Axogen
|
$48.3M | $0.02 | 10.96% | -76% | $24.43 |
|
ELMD
Electromed
|
$15.8M | -- | 12.26% | -- | $37.00 |
|
IRIX
IRIDEX
|
$12.8M | -$0.12 | -2.72% | -18.18% | -- |
|
MYO
Myomo
|
$9.2M | -$0.08 | 21.89% | -258.33% | $9.05 |
|
STXS
Stereotaxis
|
$6.9M | -$0.07 | 72.15% | -3.57% | $4.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TMDX
TransMedics Group
|
$123.34 | $126.71 | $4.2B | 90.69x | $0.00 | 0% | 9.23x |
|
AXGN
Axogen
|
$10.94 | $24.43 | $498.3M | -- | $0.00 | 0% | 2.52x |
|
ELMD
Electromed
|
$20.35 | $37.00 | $170.7M | 25.76x | $0.00 | 0% | 2.97x |
|
IRIX
IRIDEX
|
$0.99 | -- | $16.6M | -- | $0.00 | 0% | 0.34x |
|
MYO
Myomo
|
$3.21 | $9.05 | $115.5M | -- | $0.00 | 0% | 3.24x |
|
STXS
Stereotaxis
|
$2.02 | $4.50 | $173.7M | -- | $0.00 | 0% | 6.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TMDX
TransMedics Group
|
65.7% | 3.653 | 22.41% | 8.13x |
|
AXGN
Axogen
|
31.17% | 1.036 | 5.67% | 2.22x |
|
ELMD
Electromed
|
-- | 2.545 | -- | 4.79x |
|
IRIX
IRIDEX
|
81.05% | 1.797 | 21.92% | 1.11x |
|
MYO
Myomo
|
-- | 2.360 | -- | 2.24x |
|
STXS
Stereotaxis
|
-- | 1.450 | -- | 0.62x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TMDX
TransMedics Group
|
$88.2M | $27.4M | 6.8% | 23.22% | 21% | -$29.9M |
|
AXGN
Axogen
|
$34.9M | -$1.7M | -4.88% | -7.2% | -3.26% | -$13.8M |
|
ELMD
Electromed
|
$12.2M | $2.1M | 16.57% | 16.57% | 13.65% | $2.2M |
|
IRIX
IRIDEX
|
$5.1M | -$205K | -140.14% | -218.69% | -1.72% | -$1.2M |
|
MYO
Myomo
|
$6.6M | -$3.5M | -38.11% | -38.11% | -35.81% | -$3.3M |
|
STXS
Stereotaxis
|
$4.1M | -$5.9M | -174.6% | -174.6% | -79.35% | -$1.8M |
TransMedics Group vs. Competitors
-
Which has Higher Returns TMDX or AXGN?
Axogen has a net margin of 17.89% compared to TransMedics Group's net margin of -7.9%. TransMedics Group's return on equity of 23.22% beat Axogen's return on equity of -7.2%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group61.47% $0.70 $776.4M AXGNAxogen71.94% -$0.08 $153.1M -
What do Analysts Say About TMDX or AXGN?
TransMedics Group has a consensus price target of $126.71, signalling upside risk potential of 2.74%. On the other hand Axogen has an analysts' consensus of $24.43 which suggests that it could grow by 123.3%. Given that Axogen has higher upside potential than TransMedics Group, analysts believe Axogen is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 AXGNAxogen5 0 0 -
Is TMDX or AXGN More Risky?
TransMedics Group has a beta of 1.906, which suggesting that the stock is 90.573% more volatile than S&P 500. In comparison Axogen has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.457%.
-
Which is a Better Dividend Stock TMDX or AXGN?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or AXGN?
TransMedics Group quarterly revenues are $143.5M, which are larger than Axogen quarterly revenues of $48.6M. TransMedics Group's net income of $25.7M is higher than Axogen's net income of -$3.8M. Notably, TransMedics Group's price-to-earnings ratio is 90.69x while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 9.23x versus 2.52x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group9.23x 90.69x $143.5M $25.7M AXGNAxogen2.52x -- $48.6M -$3.8M
-
Which has Higher Returns TMDX or ELMD?
Electromed has a net margin of 17.89% compared to TransMedics Group's net margin of 12.06%. TransMedics Group's return on equity of 23.22% beat Electromed's return on equity of 16.57%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group61.47% $0.70 $776.4M ELMDElectromed77.97% $0.21 $43.9M -
What do Analysts Say About TMDX or ELMD?
TransMedics Group has a consensus price target of $126.71, signalling upside risk potential of 2.74%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 81.82%. Given that Electromed has higher upside potential than TransMedics Group, analysts believe Electromed is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 ELMDElectromed2 0 0 -
Is TMDX or ELMD More Risky?
TransMedics Group has a beta of 1.906, which suggesting that the stock is 90.573% more volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.
-
Which is a Better Dividend Stock TMDX or ELMD?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or ELMD?
TransMedics Group quarterly revenues are $143.5M, which are larger than Electromed quarterly revenues of $15.7M. TransMedics Group's net income of $25.7M is higher than Electromed's net income of $1.9M. Notably, TransMedics Group's price-to-earnings ratio is 90.69x while Electromed's PE ratio is 25.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 9.23x versus 2.97x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group9.23x 90.69x $143.5M $25.7M ELMDElectromed2.97x 25.76x $15.7M $1.9M
-
Which has Higher Returns TMDX or IRIX?
IRIDEX has a net margin of 17.89% compared to TransMedics Group's net margin of -14.17%. TransMedics Group's return on equity of 23.22% beat IRIDEX's return on equity of -218.69%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group61.47% $0.70 $776.4M IRIXIRIDEX42.49% -$0.10 $4.5M -
What do Analysts Say About TMDX or IRIX?
TransMedics Group has a consensus price target of $126.71, signalling upside risk potential of 2.74%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 101.98%. Given that IRIDEX has higher upside potential than TransMedics Group, analysts believe IRIDEX is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 IRIXIRIDEX0 0 0 -
Is TMDX or IRIX More Risky?
TransMedics Group has a beta of 1.906, which suggesting that the stock is 90.573% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.819%.
-
Which is a Better Dividend Stock TMDX or IRIX?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or IRIX?
TransMedics Group quarterly revenues are $143.5M, which are larger than IRIDEX quarterly revenues of $11.9M. TransMedics Group's net income of $25.7M is higher than IRIDEX's net income of -$1.7M. Notably, TransMedics Group's price-to-earnings ratio is 90.69x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 9.23x versus 0.34x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group9.23x 90.69x $143.5M $25.7M IRIXIRIDEX0.34x -- $11.9M -$1.7M
-
Which has Higher Returns TMDX or MYO?
Myomo has a net margin of 17.89% compared to TransMedics Group's net margin of -35.24%. TransMedics Group's return on equity of 23.22% beat Myomo's return on equity of -38.11%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group61.47% $0.70 $776.4M MYOMyomo67.23% -$0.08 $21.7M -
What do Analysts Say About TMDX or MYO?
TransMedics Group has a consensus price target of $126.71, signalling upside risk potential of 2.74%. On the other hand Myomo has an analysts' consensus of $9.05 which suggests that it could grow by 181.93%. Given that Myomo has higher upside potential than TransMedics Group, analysts believe Myomo is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 MYOMyomo3 0 0 -
Is TMDX or MYO More Risky?
TransMedics Group has a beta of 1.906, which suggesting that the stock is 90.573% more volatile than S&P 500. In comparison Myomo has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.336%.
-
Which is a Better Dividend Stock TMDX or MYO?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or MYO?
TransMedics Group quarterly revenues are $143.5M, which are larger than Myomo quarterly revenues of $9.8M. TransMedics Group's net income of $25.7M is higher than Myomo's net income of -$3.5M. Notably, TransMedics Group's price-to-earnings ratio is 90.69x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 9.23x versus 3.24x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group9.23x 90.69x $143.5M $25.7M MYOMyomo3.24x -- $9.8M -$3.5M
-
Which has Higher Returns TMDX or STXS?
Stereotaxis has a net margin of 17.89% compared to TransMedics Group's net margin of -77.93%. TransMedics Group's return on equity of 23.22% beat Stereotaxis's return on equity of -174.6%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group61.47% $0.70 $776.4M STXSStereotaxis54.39% -$0.07 $8.2M -
What do Analysts Say About TMDX or STXS?
TransMedics Group has a consensus price target of $126.71, signalling upside risk potential of 2.74%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 122.77%. Given that Stereotaxis has higher upside potential than TransMedics Group, analysts believe Stereotaxis is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 STXSStereotaxis2 0 0 -
Is TMDX or STXS More Risky?
TransMedics Group has a beta of 1.906, which suggesting that the stock is 90.573% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.088%.
-
Which is a Better Dividend Stock TMDX or STXS?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or STXS?
TransMedics Group quarterly revenues are $143.5M, which are larger than Stereotaxis quarterly revenues of $7.5M. TransMedics Group's net income of $25.7M is higher than Stereotaxis's net income of -$5.8M. Notably, TransMedics Group's price-to-earnings ratio is 90.69x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 9.23x versus 6.33x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group9.23x 90.69x $143.5M $25.7M STXSStereotaxis6.33x -- $7.5M -$5.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Forge Global Stock Go Down?
Shares of Forge Global (NYSE:FRGE), a platform that allows accredited…
Is GlobalFoundries On The Verge Of A Breakout?
GLOBALFOUNDRIES Inc. (NASDAQ:GFS) is as a semiconductor foundry whose chips…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
66
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 45x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
54
AAP alert for May 23
Advance Auto Parts [AAP] is down 3.68% over the past day.
Buy
67
IONQ alert for May 23
IonQ [IONQ] is down 2.99% over the past day.
Buy
75
URBN alert for May 23
Urban Outfitters [URBN] is down 2.27% over the past day.
